Holen Sie sich die Stockscreener-App
2.115
0.24%
-0.005
Schlusskurs vom Vortag:
$2.12
Offen:
$2.12
24-Stunden-Volumen:
132.73K
Relative Volume:
0.62
Marktkapitalisierung:
$44.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.79M
KGV:
-4.4044
EPS:
-0.4802
Netto-Cashflow:
$-8.94M
1W Leistung:
-1.17%
1M Leistung:
-0.70%
6M Leistung:
-46.18%
1J Leistung:
-35.12%
1-Tages-Spanne:
$2.07
$2.135
1-Wochen-Bereich:
$2.05
$2.20
52-Wochen-Spanne:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Firmenname
Grace Therapeutics Inc
Sektor
Branche
Telefon
609-322-1602
Adresse
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.13 | 44.60M | 0 | -7.79M | -8.94M | -0.4802 |
VRTX
Vertex Pharmaceuticals Inc
|
521.32 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.44 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.73 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.36 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.19 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2020-09-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-06 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2020-01-13 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-08-29 | Eingeleitet | B. Riley FBR | Buy |
| 2019-07-18 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Grace Therapeutics Inc Aktie (GRCE) Neueste Nachrichten
Grace Therapeutics (GRCE) Dips 1.0% to $2.08, Holds Above Key SupportPullback Trade - dars.gov.et
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - Stocktwits
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference - The Manila Times
A drug company CEO's presentation goes online Sept. 11. He'll meet investors in New York. - Stock Titan
Grace Therapeutics (GRCE) awards finance chief options vesting over three years - Stock Titan
Grace Therapeutics (GRCE) grants CEO options at $2.12 - Stock Titan
Grace Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Opaleye Management Inc. Expands Stake in Grace Therapeutics Inc (GRCE) Despite Market Headwinds - GuruFocus
Grace TherapeuticsSelling Stockholders May Resell Up To 4,761,904 Shares Of Common StockSEC Filing - TradingView
Grace (GRCE) Quarterly Results: EPS Lands Above Forecast at the Close; Post-Earnings: The Stock Ends Up 2.80% in the Latest SessionCore Business Growth - vinanet.vn
Grace Therapeutics files prospectus for 4.762m share sale - scanx.trade
Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher - vinanet.vn
Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest ReadingTech Earnings Analysis - vinanet.vn
Opaleye Management buys $24,206 of Grace Therapeutics stock By Investing.com - Investing.com Canada
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares - Stock Titan
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
GRCE Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 74.42% EPS SurpriseManagement Guidance Update - vinanet.vn
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 74.42% Surprise Despite No RevenueGuidance vs Actual - vinanet.vn
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
GRCE Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 74.4%Earnings Weakness Phase - vinanet.vn
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - quiverquant.com
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - Pluang
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
GRCE Q2 2026 Earnings: 74.4% EPS Surprise Signals Stronger Cost DisciplineEarnings Per Share - vinanet.vn
Finanzdaten der Grace Therapeutics Inc-Aktie (GRCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):